Patents by Inventor David B. Kanne

David B. Kanne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR ACTIVATING "STIMULATOR OF INTERFERON GENE"-DEPENDENT SIGNALLING
    Publication number: 20200282049
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce STING-dependent type I interferon production, wherein the cyclic purine dinuclotides present in the composition are substantially pure 2?,5?,2?,5? and 2?,5?,3?,5? CDNs, and prefereably Rp,Rp stereosiomers thereof.
    Type: Application
    Filed: May 18, 2020
    Publication date: September 10, 2020
    Applicants: ADURO BIOTECH, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas W. Dubensky, JR., David B. Kanne, Meredith Lai Ling Leong, Edward Emile Lemmens, Laura H. Glickman, Russell E. Vance
  • Compositions and methods for activating “stimulator of interferon gene”-dependent signalling
    Patent number: 10653774
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are substantially pure 2?,5?,2?,5? and 2?,5?,3?,5? CDNs, and preferably Rp,Rp stereoisomers thereof.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: May 19, 2020
    Assignees: ADURO BIOTECH, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas W. Dubensky, Jr., David B. Kanne, Meredith Lai Ling Leong, Edward Emile Lemmens, Laura H. Glickman, Russell E. Vance
  • Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
    Patent number: 10414789
    Abstract: It is an object of the present invention to provide novel and highly active cyclic-di-nucleotide (CDN) immune stimulators that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides that induce STING-dependent TBK1 activation, wherein the cyclic purine dinuclotides present in the composition are substantially pure Rp,Rp or Rp,Sp stereoisomers, and particularly substantially pure Rp,Rp, or RpSp CDN thiophosphate diastereomers.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: September 17, 2019
    Assignee: ADURO BIOTECH, INC.
    Inventors: Thomas W. Dubensky, Jr., David B. Kanne, Meredith Lai Ling Leong, Edward Emile Lemmens, Laura Hix Glickman
  • Compositions and methods for inhibiting “stimulator of interferon gene”-dependent signalling
    Patent number: 10189873
    Abstract: The invention provides compounds of the purine cyclic dinucleotide (CDN) class, useful as inhibitors of the STING (Stimulator of Interferon Genes) pathway, and methods of their administration to individuals in need thereof.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: January 29, 2019
    Assignee: ADURO BIOTECH, INC.
    Inventors: Thomas W. Dubensky, Jr., David B. Kanne
  • COMPOSITIONS AND METHODS FOR ACTIVATING "STIMULATOR OF INTERFERON GENE"-DEPENDENT SIGNALLING
    Publication number: 20170333552
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are substantially pure 2?,5?,2?,5? and 2?,5?,3?,5? CDNs, and preferably Rp,Rp stereoisomers thereof.
    Type: Application
    Filed: July 31, 2017
    Publication date: November 23, 2017
    Applicants: ADURO BIOTECH, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas W. Dubensky, JR., David B. Kanne, Meredith Lai Ling Leong, Edward Emile Lemmens, Laura H. Glickman, Russell E. Vance
  • COMPOSITIONS COMPRISING CYCLIC PURINE DINUCLEOTIDES HAVING DEFINED STEREOCHEMISTRIES AND METHODS FOR THEIR PREPARATION AND USE
    Publication number: 20170283454
    Abstract: It is an object of the present invention to provide novel and highly active cyclic-di-nucleotide (CDN) immune stimulators that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides that induce STING-dependent TBK1 activation, wherein the cyclic purine dinuclotides present in the composition are substantially pure Rp,Rp or Rp,Sp stereoisomers, and particularly substantially pure Rp,Rp, or RpSp CDN thiophosphate diastereomers.
    Type: Application
    Filed: June 22, 2017
    Publication date: October 5, 2017
    Inventors: Thomas W. Dubensky, JR., David B. Kanne, Meredith Lai Ling Leong, Edward Emile Lemmens, Laura Hix Glickman
  • Compositions and methods for activating stimulator of interferon gene-dependent signalling
    Patent number: 9724408
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are substantially pure 2?,5?,2?,5? and 2?,5?,3?,5? CDNs, and preferably Rp,Rp stereoisomers thereof.
    Type: Grant
    Filed: May 18, 2014
    Date of Patent: August 8, 2017
    Assignees: ADURO BIOTECH, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas W. Dubensky, Jr., David B. Kanne, Meredith Lai Ling Leong, Edward Emile Lemmens, Laura H. Glickman, Russell E. Vance
  • COMPOSITIONS AND METHODS FOR INHIBITING "STIMULATOR OF INTERFERON GENE" -DEPENDENT SIGNALLING
    Publication number: 20170218008
    Abstract: The present invention provides cyclic-di-nucleotide (CDN) compounds that inhibit signaling at a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides which inhibit STING-dependent TBK1 activation and the resulting production of type I interferon.
    Type: Application
    Filed: January 20, 2017
    Publication date: August 3, 2017
    Inventors: Thomas W. Dubensky, JR., David B. Kanne
  • Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
    Patent number: 9695212
    Abstract: It is an object of the present invention to provide novel and highly active cyclic-di-nucleotide (CDN) immune stimulators that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides that induce STING-dependent TBK1 activation, wherein the cyclic purine dinuclotides present in the composition are substantially pure Rp,Rp or Rp,Sp stereoisomers, and particularly substantially pure Rp,Rp, or RpSp CDN thiophosphate diastereomers.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: July 4, 2017
    Assignee: Aduro Biotech, Inc.
    Inventors: Thomas W. Dubensky, Jr., David B. Kanne, Meredith Lai Ling Leong, Edward Emile Lemmens, Laura Hix Glickman
  • Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
    Patent number: 9549944
    Abstract: The present invention provides cyclic-di-nucleotide (CDN) compounds that inhibit signaling at a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides which inhibit STING-dependent TBK1 activation and the resulting production of type I interferon.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: January 24, 2017
    Assignee: ADURO BIOTECH, INC.
    Inventors: Thomas W. Dubensky, Jr., David B. Kanne
  • COMPOSITIONS AND METHODS FOR ACTIVATING STIMULATOR OF INTERFERON GENE-DEPENDENT SIGNALLING
    Publication number: 20150056224
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are substantially pure 2?,5?,2?,5? and 2?,5?,3?,5? CDNs, and preferably Rp,Rp stereosiomers thereof.
    Type: Application
    Filed: May 18, 2014
    Publication date: February 26, 2015
    Applicants: ADURO BIOTECH, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas W. Dubensky, JR., David B. Kanne, Meredith Lai Ling Leong, Edward Emile Lemmens, Laura H. Glickman, Russell E. Vance
  • COMPOSITIONS AND METHODS FOR INHIBITING "STIMULATOR OF INTERFERON GENE" -DEPENDENT SIGNALLING
    Publication number: 20140341976
    Abstract: The present invention provides cyclic-di-nucleotide (CDN) compounds that inhibit signaling at a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides which inhibit STING-dependent TBK1 activation and the resulting production of type I interferon.
    Type: Application
    Filed: May 19, 2014
    Publication date: November 20, 2014
    Applicant: ADURO BIOTECH, INC.
    Inventors: Thomas W. Dubensky, JR., David B. Kanne
  • COMPOSITIONS COMPRISING CYCLIC PURINE DINUCLEOTIDES HAVING DEFINED STEREOCHEMISTRIES AND METHODS FOR THEIR PREPARATION AND USE
    Publication number: 20140205653
    Abstract: It is an object of the present invention to provide novel and highly active cyclic-di-nucleotide (CDN) immune stimulators that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides that induce STING-dependent TBK1 activation, wherein the cyclic purine dinuclotides present in the composition are substantially pure Rp,Rp or Rp,Sp stereoisomers, and particularly substantially pure Rp,Rp, or RpSp CDN thiophosphate diastereomers.
    Type: Application
    Filed: December 13, 2013
    Publication date: July 24, 2014
    Applicant: Aduro Biotech, Inc.
    Inventors: Thomas W. Dubensky, JR., David B. Kanne, Meredith Lai Ling Leong, Edward Emile Lemmens, Laura Hix Glickman
  • Squalane and isosqualane compositions and methods for preparing the same
    Patent number: 8586814
    Abstract: Provided herein are methods comprising catalytic dimerization of ?-farnesene to obtain squalane and/or isosqualane. Compositions comprising squalane and/or isosqualane are provided. In certain embodiments, squalane and isosqualane prepared by the methods provided herein can be useful for applications in cosmetic industry and/or in the lubricants industry.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: November 19, 2013
    Assignee: Amyris, Inc.
    Inventors: Karl Fisher, Susan Jessica Schofer, David B. Kanne
  • SQUALANE AND ISOSQUALANE COMPOSITIONS AND METHODS FOR PREPARING THE SAME
    Publication number: 20110287988
    Abstract: Provided herein are methods comprising catalytic dimerization of ?-farnesene to obtain squalane and/or isosqualane. Compositions comprising squalane and/or isosqualane are provided. In certain embodiments, squalane and isosqualane prepared by the methods provided herein can be useful for applications in cosmetic industry and/or in the lubricants industry.
    Type: Application
    Filed: May 20, 2011
    Publication date: November 24, 2011
    Inventors: Karl Fisher, Susan Jessica Schofer, David B. Kanne
  • LIGAND CONJUGATED THERMOTHERAPY SUSCEPTORS AND METHODS FOR PREPARING SAME
    Publication number: 20090317408
    Abstract: Magnetic nanoparticles exhibiting enhanced heating ability in thermotherapeutic applications are described, as are several strategies to conjugate such nanoparticles. Methods for using conjugated nanoparticles are also provided.
    Type: Application
    Filed: December 15, 2008
    Publication date: December 24, 2009
    Applicant: Aduro BioTech
    Inventors: Robert Ivkov, Cordula Gruttner, Knut Meuller, Joachim Teller, Fritz Westphal, Allan Foreman, David B. Kanne, Hsiao-Ling Chin, Paul C. Chinn
  • 3-substituted pyridine compounds and derivatives thereof
    Patent number: 5763357
    Abstract: Herbicidal 3-substituted pyridine compounds and derivatives thereof of the formula: ##STR1## wherein Ar is a substituted or unsubstituted 5- or 6-membered heteroaryl group having 1, 2 or 3 ring nitrogen atoms with the remainder of the ring atoms being carbon; a substituted or unsubstituted 5-membered heteroaryl group having a ring heteroatom of oxygen or sulfur with the remainder of the ring atoms being carbon; or a substituted or unsubstituted 5-membered heteroaryl group having one ring nitrogen atom and either an oxygen or sulfur ring heteroatom with the remainder of the ring atoms being carbon. Herbicidal compositions containing such 3-substituted pyridine compounds and derivatives thereof and methods of controlling undesirable vegetation employing these compounds and derivatives are also disclosed. The compounds in which XR is hydroxyl are also useful as intermediates for producing the disclosed 3-substituted pyridine derivatives.
    Type: Grant
    Filed: November 1, 1996
    Date of Patent: June 9, 1998
    Assignee: Zeneca Limited
    Inventors: Hsiao-Ling M. Chin, Nhan H. Nguyen, David B. Kanne, David L. Lee
  • Herbicidal 5-substituted pyrimidine compounds and derivatives thereof
    Patent number: 5714438
    Abstract: Herbicidal 5-substituted pyrimidine compounds and derivatives thereof of the formula: ##STR1## Herbicidal compositions containing such 5-substituted pyrimidine compounds and derivatives thereof and methods of controlling undesirable vegetation using these compounds and derivatives are also disclosed. The compounds in which XR is hydroxyl are also useful as intermediates for producing the 5-substituted pyrimidine derivatives of the invention.
    Type: Grant
    Filed: December 5, 1996
    Date of Patent: February 3, 1998
    Assignee: Zeneca Limited
    Inventors: David B. Kanne, Michael P. Prisbylla
  • 4-cycloalkyl-5-substituted pyrimidine compounds useful as crop protection agents
    Patent number: 5707930
    Abstract: Herbicidal 4-cycloalkyl-5-substituted pyrimidine compounds of the formula ##STR1## are described. Herbicidal compositions containing such substituted-pyrimidinyl compounds and methods of controlling undesirable vegetation employing these compounds are also disclosed. The compounds in which XR, is hydroxyl are also useful as intermediates for producing the disclosed substituted-pyrimidinyl derivatives.
    Type: Grant
    Filed: September 16, 1996
    Date of Patent: January 13, 1998
    Assignee: Zeneca Limited
    Inventors: Raymond A. Felix, Hsiao-Ling M. Chin, Frank X. Woolard, David L. Lee, David B. Kanne
  • Herbicidal hydroxybenzyl-substituted heteroaryl compounds and derivatives thereof
    Patent number: 5672567
    Abstract: Herbicidal substituted hydroxybenzyl-heteroaryl compounds and derivatives thereof of the formula ##STR1## wherein Ar is a substituted or unsubstituted 5- or 6-membered heteroaryl group having 2 or 3 ring nitrogen atoms or a substituted or unsubstituted 5-membered heteroaryl group having two ring heteroatoms, one of the ring heteroatoms being nitrogen and the other being sulfur or oxygen. Herbicidal compositions containing such substituted hydroxybenzyl-heteroaryl compounds and derivatives thereof and methods of controlling undesirable vegetation employing these compounds and derivatives are also disclosed. The compounds in which XR is hydroxyl are also useful as intermediates for producing the disclosed substituted hydroxybenzyl-heteroaryl derivatives.
    Type: Grant
    Filed: March 25, 1996
    Date of Patent: September 30, 1997
    Assignee: Zeneca Limited
    Inventors: Hsiao-Ling M. Chin, Yi-Qiu Wei, Nhan H. Nguyen, David B. Kanne